

Effectiveness of GLP-1 analogues compared to DPP-4 inhibitors for beta cell function and diabetes related complications among adults with type 2 diabetes: a systematic review and meta-analysis



Susan Bellman,^{1,2} Jared Campbell² and Edoardo Aromataris²

¹ MClInSc candidate, ² The Joanna Briggs Institute, Faculty of Health Sciences, The University of Adelaide, SA 5005

Introduction


Continued loss of beta cell function is responsible for progressive deterioration of plasma glucose control, and complications characteristic of type 2 diabetes.¹ Research has indicated that a decline in beta cell function occurs early in the course of type 2 diabetes.¹ (Figure 1)

There is increasing clinical evidence that the incretin hormone glucagon-like peptide-1 (GLP-1) can improve beta cell function,¹ however clinical use of GLP-1 in its native form is hampered by its rapid, enzymatic inactivation by dipeptidyl peptidase-4 (DPP-4).²

Two classes of incretin-based antihyperglycaemic agents DPP-4 inhibitors and GLP-1 analogues utilise the biological potential of GLP-1 in two ways:

- GLP-1 analogues are resistant to DPP-4 inactivation and mimic the action of naturally occurring GLP-1
- DPP-4 inhibitors block enzymatic DPP-4 action and thereby prolong the activity of endogenous GLP-1² (Figure 2)

Figure 1. Natural history of type 2 diabetes. (A) Elevations in blood glucose level over time. (B) Progression from compensatory beta cell function to beta cell decline and failure resulting in a decrease in insulin concentration. Shaded area represents normal blood glucose range.



Aim

The aim of this systematic review was to provide a comprehensive synthesis of randomised clinical studies comparing the effectiveness of GLP-1 analogues to DPP-4 inhibitors on beta cell function and diabetes related complications.


Method

A search of PubMed, EMBASE and national and international clinical trials databases was conducted. Randomised controlled trials were included that compared GLP-1 analogues to DPP-4 inhibitors, either alone or in combination with metformin, in adults with type 2 diabetes. Primary outcomes of interest were:

- beta cell function measured by hyperglycaemic clamp technique, homeostasis assessment model (HOMA), measures of C-peptide and proinsulin to insulin plasma concentration ratio
- glycated haemoglobin (HbA1c)
- fasting and postprandial plasma glucose levels.

Secondary outcomes of interest were diabetes related complications (neuropathy, nephropathy and retinopathy) adverse drug events and mortality.

Figure 2. Schematic diagram explaining: (A) physiological secretion of GLP-1 from the gut, (B) its binding to GLP-1 receptors on the pancreatic beta cells and (C) its enzymatic degradation by DPP-4. GLP-1 analogue (D) binds to and activates GLP-1 receptor, DPP-4 inhibitors (E) prevent the degradation of biological GLP-1 and thereby enhance its activity on the pancreas. (Adapted from:- Nauck M, Vilsboll T, Gallwitz B. Incretin-Based Therapies. Diabetes Care. 2009;32(Suppl):S223-S231).



Results

Figure 3. Meta-analysis of effects on beta cell function as measured by homeostasis model assessment (HOMA-B%) with GLP-1 analogue versus DPP-4 inhibitor for duration of 26 weeks.




Figure 4. Meta-analysis of effects on HbA1c as measured by % with GLP-1 analogue versus DPP-4 inhibitor for duration of 26 weeks.





Figure 5. Meta-analysis of effects on fasting plasma glucose levels as measured by mmol/L with GLP-1 analogue versus DPP-4 inhibitors for duration of 26 weeks.



A total of eight randomised controlled trials were included in the systematic review, including two unpublished studies and three multi-arm studies. Treatment duration ranged from eight weeks to 52 weeks. Four different GLP-1 analogues were used in the retrieved studies (lixisenatide, liraglutide, dulaglutide and exenatide) while the same DPP-4 inhibitor (sitagliptin) was used as the active comparator throughout all included studies.

Meta-analysis results showed that, at 26 weeks, GLP-1 analogue compared to DPP-4 inhibitor was associated with:

- more favourable improvements in beta cell function as measured by HOMA (Figure 3)
- Greater reduction in HbA1c (Figure 4)
- Greater reduction in fasting plasma glucose (Figure 5)

No comparative outcome data were obtained for postprandial plasma glucose levels, or diabetes related complications. DPP-4 inhibitors had fewer gastrointestinal adverse events compared to GLP-1 analogues. There were no difference in headache and infection adverse events.

Conclusion

The findings showed that GLP-1 analogues had greater beneficial effects on pancreatic beta cell function, HbA1c and fasting plasma glucose levels than DPP-4 inhibitors, however caused more gastrointestinal adverse events.

References

1. Mudaliar S. Choice of early treatment regimen and impact on β -cell preservation in type 2 diabetes. Int J Clin Pract. 2013 Sep; 67(9):876-887
2. Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;1-11
3. Nauck et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial. Diabetes Care. 2014 Apr; 1-10
4. Pratley et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010; 375:1447-56
5. Bergental et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010; 376:431-39
6. Gudipaty et al. Effect of exenatide, sitagliptin or glimepiride on β -cell secretory capacity in early type 2 diabetes. Diabetes Care. 2014;1-8
7. Russell-Jones et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4). Diabetes Care 2012; 35: 252-258

Contact Information

Susan Bellman MNutrDiet, BPharm, GradCertDiabEdM
Email susan.bellman@adelaide.edu.au